Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Payer

- PMLiVE

CAR-T therapies show long-term benefits in lymphoma

Novartis’ Kymriah and Gilead’s Yescarta both achieve significant complete response in lymphoma patients

Roche Basel Switzerland

Roche claims its own CAR-T first with orphan drug Actemra

Comes as FDA approves the first CAR-T therapy from Novartis

- PMLiVE

Novartis claims first CAR-T approval, setting $475k price tag

Kymriah receives FDA nod to treat ALL patients

- PMLiVE

Gilead makes $11.9bn play for CAR-T specialist Kite

The agreement is due to close in this year’s fourth quarter

- PMLiVE

Intriguing data with Juno’s new CAR-T therapy

Suggests a long treatment effect from the biotech's JCAR017 candidate

- PMLiVE

Novartis’ CAR-T clears FDA panel with relative ease

Puts tisagenlecleucel-T on course to be first approved personalised CAR-T therapy

- PMLiVE

Connecting the dots

What happens ‘here’ impacts what happens ‘there’

Novartis day

Novartis files CAR-T therapy in US, with swift review

CTL109 candidate gets FDA priority review status

Roche Basel Switzerland

Roche sets disruptive price for new MS drug Ocrevus in US

Firm will significantly under cut rivals like Merck's Rebif

- PMLiVE

Servier cleared to start US trials CAR-T therapy

FDA rules studies of its Pfizer-partnered drug can be resumed

Research Partnership has been ranked in the Pharma Times Pharma Fast 50

Industry Magazine Pharma Times has partnered with Catalyst Corporate Finance to publish a detailed analysis of the 50 fastest growing private, independently owned pharma companies in the UK and Research...

Research Partnership

- PMLiVE

BIA calls for additional UK government support for life sciences

Addresses R&D tax credits for SMEs, reimbursement and innovation funding expansion

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links